These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Clinical Pharmacokinetics of Ponesimod, a Selective S1P1 Receptor Modulator, in the Treatment of Multiple Sclerosis. Kruger TM; Valenzuela B; Thompson CD; Ouwerkerk-Mahadevan S; Ruixo JJP Clin Pharmacokinet; 2023 Nov; 62(11):1533-1550. PubMed ID: 37776485 [TBL] [Abstract][Full Text] [Related]
24. Three different up-titration regimens of ponesimod, an S1P1 receptor modulator, in healthy subjects. Scherz MW; Brossard P; D'Ambrosio D; Ipek M; Dingemanse J J Clin Pharmacol; 2015 Jun; 55(6):688-97. PubMed ID: 25612299 [TBL] [Abstract][Full Text] [Related]
25. Mass balance, pharmacokinetics and metabolism of the selective S1P1 receptor modulator ponesimod in humans. Reyes M; Hoch M; Brossard P; Wagner-Redeker W; Miraval T; Dingemanse J Xenobiotica; 2015 Feb; 45(2):139-49. PubMed ID: 25188442 [TBL] [Abstract][Full Text] [Related]
26. S1P Birker-Robaczewska M; Bolli M; Rey M; de Kanter R; Kohl C; Lescop C; Boucher M; Poirey S; Steiner B; Nayler O Mol Pharmacol; 2018 Feb; 93(2):109-118. PubMed ID: 29203519 [TBL] [Abstract][Full Text] [Related]
27. Pharmacological modulation of peripheral T and B lymphocytes by a selective sphingosine 1-phosphate receptor-1 modulator. Moberly JB; Rohatagi S; Zahir H; Hsu C; Noveck RJ; Truitt KE J Clin Pharmacol; 2012 Jul; 52(7):996-1006. PubMed ID: 21566200 [TBL] [Abstract][Full Text] [Related]
28. Biological variability of lymphocyte subsets of human adults' blood. Tosato F; Bernardi D; Sanzari MC; Pantano G; Plebani M Clin Chim Acta; 2013 Sep; 424():159-63. PubMed ID: 23770423 [TBL] [Abstract][Full Text] [Related]
29. Limited effect of eicosapentaenoic acid on T-lymphocyte and natural killer cell numbers and functions in healthy young males. Miles EA; Banerjee T; Wells SJ; Calder PC Nutrition; 2006 May; 22(5):512-9. PubMed ID: 16600816 [TBL] [Abstract][Full Text] [Related]
30. Reference ranges of lymphocyte subsets in healthy adults and adolescents with special mention of T cell maturation subsets in adults of South Florida. Valiathan R; Deeb K; Diamante M; Ashman M; Sachdeva N; Asthana D Immunobiology; 2014 Jul; 219(7):487-96. PubMed ID: 24661720 [TBL] [Abstract][Full Text] [Related]
31. Effect of Hepatic or Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Ponesimod, a Selective S1P1 Receptor Modulator. Guérard N; Zwingelstein C; Hoch M; Dingemanse J Basic Clin Pharmacol Toxicol; 2016 May; 118(5):356-68. PubMed ID: 26525450 [TBL] [Abstract][Full Text] [Related]
32. Cardiodynamic Interactions between Two S1P Juif PE; Ufer M; Dingemanse J Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31266149 [TBL] [Abstract][Full Text] [Related]
34. Alteration of circadian rhythmicity of CD3+CD4+ lymphocyte subpopulation in healthy aging. Mazzoccoli G; Carughi S; Sperandeo M; Pazienza V; Giuliani F; Greco A J Biol Regul Homeost Agents; 2011; 25(3):405-16. PubMed ID: 22023765 [TBL] [Abstract][Full Text] [Related]
35. The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling. Ohno T; Hasegawa C; Nakade S; Kitagawa J; Honda N; Ogawa M Biopharm Drug Dispos; 2010 Oct; 31(7):396-406. PubMed ID: 20623701 [TBL] [Abstract][Full Text] [Related]
36. Ponesimod inhibits astrocyte-mediated neuroinflammation and protects against cingulum demyelination via S1P Kihara Y; Jonnalagadda D; Zhu Y; Ray M; Ngo T; Palmer C; Rivera R; Chun J FASEB J; 2022 Feb; 36(2):e22132. PubMed ID: 34986275 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of species difference in peripheral lymphocyte reduction effect of CS-0777, a sphingosine 1-phosphate receptor modulator, based on a pharmacokinetic/pharmacodynamic model analysis. Inaba SI; Goto M; Tanaka-Takanaka K; Tanaka H; Tomisato W; Yuita H; Doi-Komuro H; Inoue R; Oshima K; Kagari T; Shimozato T; Izumi T Biopharm Drug Dispos; 2016 Dec; 37(9):561-573. PubMed ID: 27764535 [TBL] [Abstract][Full Text] [Related]
38. Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator. Tran JQ; Hartung JP; Peach RJ; Boehm MF; Rosen H; Smith H; Brooks JL; Timony GA; Olson AD; Gujrathi S; Frohna PA J Clin Pharmacol; 2017 Aug; 57(8):988-996. PubMed ID: 28398597 [TBL] [Abstract][Full Text] [Related]
39. Seasonal modulation of the circadian time structure of circulating T and natural killer lymphocyte subsets from healthy subjects. Lévi FA; Canon C; Touitou Y; Reinberg A; Mathé G J Clin Invest; 1988 Feb; 81(2):407-13. PubMed ID: 3257498 [TBL] [Abstract][Full Text] [Related]
40. Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases. D'Ambrosio D; Freedman MS; Prinz J Ther Adv Chronic Dis; 2016 Jan; 7(1):18-33. PubMed ID: 26770667 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]